OR WAIT null SECS
February 02, 2022
Eli Lilly and Company has entered into a research and collaboration agreement with Entos Pharmaceuticals to develop new therapeutics for treating neurologic disorders.
January 31, 2022
Both Pfizer and Moderna have started clinical trials for their respective Omicron COVID-19 variant vaccine.
January 28, 2022
PhoreMost has entered into separate collaboration agreements with Polaris Quantum Biotech and NeoCura Bio-Medical Technology to discover and develop novel cancer therapeutics.
January 27, 2022
A collaboration and licensing agreement has been entered into by the Queen’s University Belfast and Ipsen.
January 25, 2022
UCB and Zogenix have agreed to an acquisition deal totaling nearly $2 billion.
January 18, 2022
In their collaboration, Bristol Myers Squibb and Prellis Biologics aim to generate human antibody libraries for select targets to enable drug discovery.
January 17, 2022
Pfizer will pay Beam $300 million upfront to conduct research on three undisclosed base editing targets in the liver, muscle, and central nervous system.
January 14, 2022
Fosun Pharma and Insilico Medicine will collaborate on AI-driven drug discovery and development of product candidates targeting multiple disease targets.
According to the company, Lumykras (Sotorasib) is the first targeted therapy approved in the European Union for patients with the KRAS G12C mutation.
The UK’s National Institute of Health and Care Excellence has recommended the use of Janssen’s Darzalex (daratumumab) in combination with Velcade (bortezomib), thalidomide and dexamethasone (DVTd) to treat adults with multiple myeloma.